Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
Ovarian Cancer, Peritoneal Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer focused on measuring recurrent ovarian cancer, platinum-resistant, platinum-sensitive, folate receptor antagonist
Eligibility Criteria
Inclusion Criteria: Patients must have disease that can be measured. Patients must meet criteria for either platinum-resistant or platinum-sensitive ovarian or peritoneal cancer. Patients may only have had one prior platinum-based chemotherapy regimen. Patients must be willing and able to stop all aspirin and NSAID medications immediately before and for a time after each treatment cycle (approx. 5-8 days) Patients must have normal kidney function. Exclusion Criteria: Patients may not have a Low Malignant Potential or Borderline Ovarian Tumor. Patients may not have received pelvic or abdominal radiotherapy. Patients must not have evidence of or received treatment for another cancer within the last 5 years. Patients must not have been diagnosed with a heart attack in the last 6 months. Patients who are unwilling or unable to take folic acid tablets, vitamin B12 injections or dexamethasone tablets.
Sites / Locations
- For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.